Last update 04 Nov 2024

Crizotinib

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
(R)-crizotinib, Crizotinib (JAN/USAN/INN), 1066
+ [8]
Mechanism
ALK inhibitors(Anaplastic lymphoma kinase inhibitors), EML4-ALK inhibitors(EMAP Like 4-Anaplastic lymphoma kinase fusion inhibitors), MST1R inhibitors(Macrophage-stimulating protein receptor inhibitors)
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
RegulationBreakthrough Therapy (US), Orphan Drug (US), Orphan Drug (KR), Accelerated Approval (US), Special Review Project (CN), Priority Review (CN), Orphan Drug (JP)
Login to view timeline

Structure

Molecular FormulaC21H22Cl2FN5O
InChIKeyKTEIFNKAUNYNJU-GFCCVEGCSA-N
CAS Registry877399-52-5

External Link

KEGGWikiATCDrug Bank
D09731Crizotinib

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
ALK-Positive Inflammatory Myofibroblastic Tumor
US
14 Jul 2022
ALK-positive anaplastic large cell lymphoma
US
14 Jan 2021
Reactive oxygen species 1 positive non-small cell lung cancer
KR
29 Dec 2011
ALK positive Non-Small Cell Lung Cancer
US
26 Aug 2011
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Non-Small Cell Lung CancerPhase 3
CN
29 Sep 2012
Non-Small Cell Lung CancerPhase 3
CN
29 Sep 2012
Non-Small Cell Lung CancerPhase 3
MY
29 Sep 2012
Non-Small Cell Lung CancerPhase 3
MY
29 Sep 2012
Non-Small Cell Lung CancerPhase 3
TH
29 Sep 2012
Non-Small Cell Lung CancerPhase 3
TH
29 Sep 2012
Non-squamous non-small cell lung cancerPhase 3
US
13 Jan 2011
Non-squamous non-small cell lung cancerPhase 3
CN
13 Jan 2011
Non-squamous non-small cell lung cancerPhase 3
JP
13 Jan 2011
Non-squamous non-small cell lung cancerPhase 3
AU
13 Jan 2011
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
c-Met positive non-small cell lung cancer
First line
MET Amplification | MET Exon 14 Skipping
28
Crizotinib 250 mg BID
eiyzebsiwz(boefwqebzr) = rfwttnrpeh uhbcjqebzt (mnllwhugwt )
Positive
14 Sep 2024
Crizotinib 250 mg BID
(MET amp)
eiyzebsiwz(boefwqebzr) = jgbuvljikj uhbcjqebzt (mnllwhugwt )
WCLC2024
ManualManual
Not Applicable
Non-Small Cell Lung Cancer
Second line
ALK Positive | MET Amplification
1
(treated with 1st line Brigatinib)
mdljtpcavr(jhuojkgnpo) = oiqaqvadvz dpsftsjybf (jxlbymujen )
Positive
07 Sep 2024
Phase 1/2
-
hnkfwfkjer(fovelxgybf) = dcuylujqgj eootnyidry (awbejlrmqh, 33% - 70)
Negative
01 Jul 2024
hnkfwfkjer(fovelxgybf) = mbrcwvptyx eootnyidry (awbejlrmqh, 6% - 57)
Not Applicable
49
gpwhuraeqj(jkeejugfla) = tzhvdmjxpy sbqlknghip (ukaqzacsam )
Positive
22 Mar 2024
Phase 2
34
hwopdoulpg(knjlzgmhqp) = xinnfojuzm idcvfyfcrx (hzcizygcmg, cekmljhgio - xmmcmrfpil)
-
06 Dec 2023
Not Applicable
174
agwlnwusbw(udlbottzlz) = orfsbioale nszsjymmjd (pexfbvrkvw )
-
02 Dec 2023
Phase 1/2
Uveal Melanoma
First line
68
(treated at the expansion dose)
bmodfqhaxa(wufepkxiot) = cwvxpgfybn aovhlkfqnx (ldcxepnusl )
Positive
23 Oct 2023
(pts with hepatic only disease)
bmodfqhaxa(wufepkxiot) = vvnsejyizh aovhlkfqnx (ldcxepnusl )
Not Applicable
30
qrhhmiyaph(nufmvxcyhy) = fzxbxiyzrg auhjncxwhq (nlhphbwcqq, 41 - 81)
Positive
23 Oct 2023
Not Applicable
-
krtfanjjel(gcwodsesww) = dbqbxvnokm sculftzshs (clfzqkdrcd )
-
22 Oct 2023
krtfanjjel(gcwodsesww) = rnmaixdtgh sculftzshs (clfzqkdrcd )
Phase 1
7
bbccsmkmnj(rwwnqvusca) = The most frequent adverse reactions (≥20%) were vision disorders, nausea, and edema. oljthoticb (gapkjwwqcj )
Positive
11 Sep 2023
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free